Selective inhibition of thromboxane synthetase reduces group-B-beta-hemolytic-streptococci-induced pulmonary hypertension in piglets.
13 newborn piglets with group-B-beta-hemolytic-streptococci (GBS)-induced pulmonary hypertension were assigned to receive either placebo (group 1) or Dazmegrel, a thromboxane synthetase inhibitor (group 2). All piglets with pulmonary hypertension had increased thromboxane B2 (TxB2) and 6-keto PGF1 alpha levels. With continued GBS infusion, the placebo group demonstrated a continued elevation of pulmonary artery pressure (PAP) and of TxB2. The Dazmegrel piglets, however, despite continued GBS infusion, demonstrated a selective decrease in PAP associated with a significant decrease in TxB2 levels and stability of systemic pressure and cardiac output. These data demonstrate that thromboxane synthetase inhibition is effective therapeutically in selectively reducing PAP.
Hammerman
C
C
University of Chicago Medical Center, Ill.
Komar
K
K
Meadow
W
W
Strates
E
E
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis; D000818:Animals; D000831:Animals, Newborn; D011464:Epoprostenol / Q000378:metabolism; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000517:prevention & control*; D007093:Imidazoles / Q000494:pharmacology; D011863:Radioimmunoassay; D013290:Streptococcal Infections / Q000150:complications*; D013552:Swine; D013929:Thromboxane B2 / Q000032:analysis / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D007093:Imidazoles; C039242:dazmegrel; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D013930:Thromboxane-A Synthase